Trials / Completed
CompletedNCT05508334
A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours
An Open-label, Non-randomised, Multicentre Study to Allow Continued Access to and Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- RemeGen Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to allow RC88 treatment of patients with advanced solid tumours to assess the safety and tolerability of clinical pharmacology studies
Detailed description
The main purpose of this Phase I study is to test RC88 at different dose levels to see if it is safe and well tolerated when given once every 2 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RC88 | Every 2 weeks for a maximum of 2 years |
Timeline
- Start date
- 2023-01-30
- Primary completion
- 2025-11-26
- Completion
- 2025-11-26
- First posted
- 2022-08-19
- Last updated
- 2025-12-22
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05508334. Inclusion in this directory is not an endorsement.